DNTH Dianthus Therapeutics, Inc. /DE/
Company Analysis
Latest News
Dianthus Therapeutics' third quarter 2026 results beat expectations with positive interim CIDP data
Dianthus Therapeutics reported third quarter 2026 financial results that exceeded analyst estimates on both the top and bottom lines. The company highlighted...
Dianthus Therapeutics Inc. Q3 2026 Earnings Preview: What Analysts Expect on November 04, 2026
Dianthus Therapeutics is expected to report a third-quarter revenue of $0.46 million and a consensus loss per share of $0.94, with the stock currently trading...
Point72 Exits $54M Stake in Dianthus Therapeutics (DNTH)
Steve Cohen's Point72 Asset Management has liquidated its entire position in Dianthus Therapeutics, a clinical-stage biotechnology company. According to...
Farallon Capital Exits Dianthus Therapeutics with $70.16M Stake Sale
In a significant portfolio shift, Farallon Capital Management fully exited its position in Dianthus Therapeutics (DNTH), selling all 836,000 of its shares. The...
RA Capital Exits $219M Stake in Dianthus Therapeutics (DNTH)
Prominent life sciences investor RA Capital Management has exited its entire position in Dianthus Therapeutics, a clinical-stage biotech firm. The fund sold...